Hypertension in pregnancy (QS35)
This standard is based on CG62 and CG107.
This standard should be read in conjunction with QS22, QS28, QS32, QS3, QS37, QS15, QS46, QS60, QS105 and QS135.
Introduction Introduction
This quality standard covers pre-pregnancy advice for women with pre-existing hypertension, as well as the antenatal, intrapartum and postnatal care of women at risk of or with hypertensive disorders of pregnancy. For more information, see the scope for this quality standard.
Why this quality standard is needed
Hypertension in pregnancy can occur for several reasons. Women might have pre-existing hypertension when they become pregnant. This includes women with hypertension at the booking appointment or before 20 weeks of pregnancy. New-onset hypertension (presenting after 20 weeks of pregnancy) is known as gestational hypertension. It can occur in isolation, or in association with proteinuria when it is known as pre-eclampsia. Pre-eclampsia is a multisystem disorder that can affect almost all maternal organ systems and the unborn baby. Women with either pre-existing hypertension or gestational hypertension are at increased risk of developing pre-eclampsia.
Hypertensive disorders in pregnancy carry risks for both the mother and the baby. They can result in substantial maternal morbidity and place women at an increased lifetime risk of cardiovascular disease. Reports on maternal and perinatal deaths show that 5% of stillbirths without congenital abnormality occurred in infants whose mothers had pre-eclampsia. Hypertension in pregnancy is associated with 8-10% of all preterm births and more than half of women with severe preeclampsia give birth preterm. Most children born of pregnancies affected by preterm preeclampsia will have restricted growth.
Pre-eclampsia becomes eclampsia when the mother develops seizures. In the UK over the last century, the rates of eclampsia appear to have fallen. Maternal deaths due to pre-eclampsia have also fallen, although hypertension in pregnancy remains one of the leading causes of maternal death in the UK. Effective and safe control of severe hypertension in pregnancy is an important aspect of critical care management.
An enquiry into maternal deaths found that the main failings in managing pre-eclampsia were lack Hypertension in pregnancy (QS35) of routine observations of blood pressure and failure to treat significantly elevated levels of blood pressure. There were a number of women with severe hypertension in pregnancy for whom junior obstetricians had failed to consult with senior staff, and there were delays in involving anaesthetic or critical care services sufficiently early.
Women with pre-existing hypertension, diabetes, chronic kidney disease or autoimmune disease, and women who had hypertension in a previous pregnancy, are at high risk of hypertension in their current pregnancy.
How this quality standard supports delivery of outcome frameworks
NICE quality standards describe high-priority areas for quality improvement in a defined care or service area. Each standard consists of a prioritised set of specific, concise and measurable statements. They draw on existing guidance, which provides an underpinning, comprehensive set of recommendations, and are designed to support the measurement of improvement. This quality standard, in conjunction with the guidance on which it is based, should contribute to the improvements outlined in the following 2 outcomes frameworks published by the Department of Tables 1-2 show the outcomes, overarching indicators and improvement areas from the frameworks that the quality standard could contribute to achieving.
T 
Coordinated services
The quality standard for hypertension in pregnancy specifies that services should be commissioned from and coordinated across all relevant agencies encompassing the whole hypertension in pregnancy care pathway. A person-centred, integrated approach to providing services is fundamental to delivering high-quality care to women with hypertension in pregnancy.
The Health and Social Care Act 2012 sets out a clear expectation that the care system should consider NICE quality standards in planning and delivering services, as part of a general duty to secure continuous improvement in quality. Commissioners and providers of health and social care
should refer to the library of NICE quality standards when designing high-quality services. Other quality standards that should also be considered when choosing, commissioning or providing a high-quality hypertension in pregnancy service are listed in Related quality standards.
T Tr raining and competencies aining and competencies
The quality standard should be read in the context of national and local guidelines on training and competencies. All healthcare practitioners involved in assessing, caring for and treating women at risk of or with hypertension in pregnancy should have sufficient and appropriate training and competencies to deliver the actions and interventions described in the quality standard.
Hypertension in pregnancy (QS35) T Terms used in this quality standard erms used in this quality standard
For the purposes of this quality standard, the following definitions apply:
Chronic h Chronic hypertension ypertension is hypertension that is present at the booking appointment or before 20 weeks of pregnancy. This could include women with pre-existing hypertension (h hypertension that is present before pregnancy ypertension that is present before pregnancy).
Gestational h Gestational hypertension ypertension is new hypertension presenting after 20 weeks of pregnancy without significant proteinuria (urinary protein:creatinine ratio greater than 30 mg/mmol or a validated 24-hour urine collection result greater than 300 mg protein).
Hypertension in pregnancy Hypertension in pregnancy includes chronic hypertension, gestational hypertension and preeclampsia.
Pre-eclampsia Pre-eclampsia is new hypertension presenting after 20 weeks of pregnancy with significant proteinuria (urinary protein:creatinine ratio greater than 30 mg/mmol or a validated 24-hour urine collection result greater than 300 mg protein).
Se Sev vere h ere hypertension ypertension is when the systolic blood pressure is 160 mmHg or greater, diastolic blood pressure is 110 mmHg or greater.
Se Sev vere pre-eclampsia ere pre-eclampsia is pre-eclampsia with severe hypertension and/or with symptoms, and/ or biochemical and/or haematological impairment.
T Treated h reated hypertension ypertension is hypertension that is treated with 1 or more antihypertensive drugs. 
Quality statement
Women of childbearing potential with treated hypertension are given information annually about safe antihypertensive treatment during pregnancy.
Rationale
Information can be provided to women who may become pregnant about safe antihypertensive treatment during pregnancy as part of an annual review of hypertension care. Women should be informed about potential risks, including the risk of congenital abnormalities, linked to particular antihypertensive drugs. This should enable women to arrange a discussion with the healthcare professional responsible for managing their hypertension about alternative antihypertensive treatments if they are planning pregnancy or become pregnant.
Quality measures

Structure Structure
Evidence of local arrangements to ensure that women of childbearing potential with treated hypertension are given information annually about safe antihypertensive treatment during pregnancy.
Data sour
Data source: ce: Local data collection.
Process Process
Proportion of women who have had treated hypertension for 12 months or longer who received information about safe antihypertensive treatment during pregnancy in the past 12 months.
Numerator -the number of women in the denominator who received information about safe antihypertensive treatment during pregnancy in the past 12 months.
Denominator -the number of women of childbearing potential who have had treated hypertension for 12 months or longer.
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What the quality statement means for service providers, healthcare practitioners and commissioners
Service pro Service providers viders ensure that systems are in place to give women of childbearing potential with treated hypertension information annually about safe antihypertensive treatment in pregnancy.
Healthcare pr Healthcare practitioners actitioners give information annually to women of childbearing potential with treated hypertension about safe antihypertensive treatment in pregnancy.
Commissioners Commissioners ensure they commission services that give information annually to women of childbearing potential with treated hypertension about safe antihypertensive treatment in pregnancy.
What the quality statement means for patients, service users and carers
W Women who are ha omen who are having treatment for h ving treatment for hypertension (high blood pressure ypertension (high blood pressure) and who ma ) and who may become y become pregnant pregnant are given information annually about safe treatment for high blood pressure during pregnancy.
Source guidance
Hypertension in pregnancy (NICE clinical guideline 107) recommendations 1.2.1.1 (key priority for implementation), 1.2.1.3 and 1.2.1.4.
Definitions of terms used in this quality statement
Safe antih Safe antihypertensiv ypertensive treatment e treatment NICE clinical guideline 107 recommends that:
Women taking angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) should be provided with information to advise that there is an increased risk of congenital abnormalities if these drugs are taken during pregnancy, and discuss other antihypertensive treatment with the healthcare professional responsible for managing their hypertension, if they are planning pregnancy.
Women taking chlorothiazide should be provided with information to advise that: there may be an increased risk of congenital abnormality and neonatal complications if these drugs are
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Women who take antihypertensive treatments other than ACE inhibitors, ARBs or chlorothiazide should be provided with information to advise that the limited evidence available has not shown an increased risk of congenital malformation with such treatments.
T Treated h reated hypertension ypertension is hypertension that is treated with 1 or more antihypertensive drug.
Equality and diversity considerations
'Childbearing potential' should be determined for women on an individual basis. Access to information about safe antihypertensive treatment during pregnancy should not be determined solely by age, because childbearing potential is also dependent on factors other than age.
Where information is provided, there must be equal access to information for all women, including those with additional needs, such as physical or learning disabilities, and those who do not speak or 
Quality statement
Pregnant women at increased risk of pre-eclampsia at the booking appointment are offered a prescription of 75 mg of aspirin to take daily from 12 weeks until birth.
Rationale
Aspirin prophylaxis, unless contraindicated, reduces the occurrence of pre-eclampsia, preterm birth and fetal and neonatal mortality in women at increased risk of developing the condition (if they have 1 high risk factor or more than 1 moderate risk factor for pre-eclampsia).
Quality measures
Structure Structure a) Evidence of local arrangements to ensure that pregnant women have their risk factors for preeclampsia identified and recorded at the booking appointment. Numerator -the number of women in the denominator whose risk factors for pre-eclampsia are identified and recorded.
Data sour
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Denominator -the number of pregnant women attending a booking appointment.
Data sour Data source: ce:
The Maternity Services Secondary Uses Dataset collects data on the following risk factors at booking: hypertension, renal disease, diabetes, autoimmune disease (global number 17200350) and obstetric diagnoses from previous pregnancies including 'severe pre-eclampsia' requiring preterm birth', 'eclampsia' and 'gestational hypertension' (global number 17200720).
b) Proportion of pregnant women at increased risk of pre-eclampsia at the booking appointment who are offered a prescription of 75 mg of aspirin (unless contraindicated) to take daily from 12 weeks until birth.
Numerator -the number of women in the denominator offered a prescription of 75 mg of aspirin to take daily from 12 weeks until birth.
Denominator -the number of pregnant women at increased risk of pre-eclampsia and without contraindications to aspirin at the booking appointment.
Local data collection.
Outcome Outcome
Incidence of pre-eclampsia in women at increased risk of developing pre-eclampsia.
The Maternity Services Secondary Uses Dataset collects data on obstetric conditions diagnosed in the current pregnancy, including severe pre-eclampsia, severe pre-eclampsia requiring preterm birth and eclampsia (global number 17203940).
What the quality statement means for service providers, healthcare practitioners and commissioners
Service pro Service providers viders ensure that systems are in place to offer pregnant women at increased risk of pre-eclampsia at the booking appointment a prescription of 75 mg of aspirin (unless contraindicated) to take daily from 12 weeks until birth.
Healthcare pr Healthcare practitioners actitioners offer pregnant women at increased risk of pre-eclampsia at the booking appointment a prescription of 75 mg of aspirin (unless contraindicated) to take daily from 12 weeks until birth.
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Commissioners Commissioners ensure they commission services that offer pregnant women at increased risk of pre-eclampsia at the booking appointment a prescription of 75 mg of aspirin (unless contraindicated) to take daily from 12 weeks until birth.
What the quality statement means for patients, service users and carers
Pregnant women who ha Pregnant women who hav ve a higher risk of de e a higher risk of dev veloping pre-eclampsia eloping pre-eclampsia (a pregnancy-related rise in blood pressure with protein in the urine that happens in some pregnancies) are offered a prescription of aspirin (unless this is unsuitable) to take every day from 12 weeks of pregnancy until their baby is born.
Source guidance
Antenatal care (NICE clinical guideline 62) recommendation 1.9.2.2.
Hypertension in pregnancy (NICE clinical guideline 107) recommendations 1.1.2.1 (key priority for implementation) and 1.1.2.2.
Definitions of terms used in this quality statement
The booking appointment The booking appointment is the appointment where the woman enters the maternity care pathway. Increased risk of pre-eclampsia Increased risk of pre-eclampsia Women are at an increased risk of pre-eclampsia if they have 1 high risk factor or more than 1 moderate risk factor for pre-eclampsia.
High risk factors include:
hypertensive disease in a previous pregnancy chronic kidney disease 
Quality statement
Women with hypertension in pregnancy have a blood pressure target set below 150/100 mmHg or, if they also have target organ damage, below 140/90 mmHg.
Rationale
Antihypertensive treatment should aim to lower blood pressure from the moderate or severe range, while avoiding excessive reductions that may affect fetal growth. It is recommended that women with evidence of target organ damage from hypertension will need a lower target blood pressure.
Quality measures
Structure Structure Commissioners Commissioners ensure they commission services that set target blood pressures for pregnant women who have hypertension of below 150/100 mmHg, or below 140/90 mmHg for women with target organ damage, and ensure that these blood pressures are maintained throughout pregnancy.
What the quality statement means for patients, service users and carers
Pregnant women with h Pregnant women with hypertension (high blood pressure ypertension (high blood pressure) ) receive treatment aimed at keeping their blood pressure below 150/100 mmHg, or below 140/90 mmHg if their high blood pressure has led to problems with their eyes, heart or kidneys.
Source guidance
Hypertension in pregnancy (NICE clinical guideline 107) recommendations 1.2.3.1 (key priority for implementation), 1.2.3.3, 1.4.1.3 (key priority for implementation) and 1.5.1.2 (key priority for implementation). 
Definitions of terms used in this quality statement
Quality statement
Pregnant women with severe hypertension are admitted for a full assessment, carried out by a healthcare professional trained in managing hypertension in pregnancy.
Rationale
Effective and safe control of severe hypertension is the most important aspect of critical care management, because the main causes of maternal death and severe maternal morbidity (including stroke) are the consequence of poorly controlled hypertension. Women with severe hypertension in pregnancy should be referred from primary care or emergency departments as soon as possible to receive assessment from healthcare professionals with expertise in managing hypertensive disorders. This is essential to ensure early identification of pre-eclampsia and the provision of critical care where it is needed.
Quality measures
Structure Structure
Evidence of local arrangements for pregnant women with severe hypertension to be admitted for a full assessment, carried out by a healthcare professional trained in managing hypertensive disorders in pregnancy.
Data sour
Process Process
Proportion of women with severe hypertension who are admitted for a full assessment, carried out by a healthcare professional trained in managing hypertensive disorders in pregnancy.
Numerator -the number of women in the denominator who are admitted for a full assessment, carried out by a healthcare professional trained in managing hypertensive disorders in pregnancy.
Denominator -the number of pregnant women with severe hypertension.
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Outcome Outcome Number of women with severe hypertension in pregnancy who have a stroke.
Data sour Data source: ce: Local data collection.
What the quality statement means for service providers, healthcare practitioners and commissioners
Service pro Service providers viders ensure that there are local arrangements for pregnant women with severe hypertension to be admitted for a full assessment, carried out by a healthcare professional trained in managing hypertensive disorders in pregnancy.
Healthcare pr Healthcare practitioners actitioners admit pregnant women with severe hypertension for a full assessment, carried out by a healthcare professional trained in managing hypertensive disorders in pregnancy.
Commissioners Commissioners ensure they commission services that admit pregnant women with severe hypertension for a full assessment, carried out by a a healthcare professional trained in managing hypertensive disorders in pregnancy.
What the quality statement means for patients, service users and carers
Pregnant women with se Pregnant women with sev vere h ere hypertension (high blood pressure ypertension (high blood pressure) ) are admitted to hospital for a full assessment, carried out by a healthcare professional trained in managing high blood pressure and related conditions in pregnancy.
Source guidance
Hypertension in pregnancy (NICE clinical guideline 107) recommendations 1.4.1.1 and 1.4.1.3 (key priority for implementation). Se Sev vere h ere hypertension ypertension Systolic blood pressure is 160 mmHg or greater, diastolic blood pressure is 110 mmHg or greater.
Definitions of terms used in this quality statement
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Quality statement 5: Admission to hospital for women with pre-eclampsia Quality statement 5: Admission to hospital for women with pre-eclampsia
Quality statement
Women with a diagnosis of pre-eclampsia are admitted to hospital and monitored daily.
Rationale
Women with pre-eclampsia should be admitted to hospital to enable their condition to be fully assessed and its progress monitored. High-quality care should include an integrated package of care for women with pre-eclampsia that includes admission and daily monitoring. Some women may need to stay in hospital until after the birth of their baby. For other women, daily monitoring may be possible if pre-eclampsia is stable and if the woman has easy access to monitoring services, and can be readmitted to hospital if her clinical condition deteriorates.
Quality measures
Structure Structure a) Evidence of local arrangements to ensure that women with a diagnosis of pre-eclampsia are admitted to hospital. Numerator -the number of women in the denominator who are admitted to hospital when preeclampsia is diagnosed.
Data sour
Denominator -the number of women with pre-eclampsia.
b) The proportion of women with pre-eclampsia who are monitored daily.
Numerator -the number of women in the denominator who are monitored daily.
Denominator -the number of women who have pre-eclampsia.
What the quality statement means for service providers, healthcare practitioners and commissioners
Service pro Service providers viders ensure that local arrangements are in place for women with a diagnosis of preeclampsia to be admitted to hospital and for their condition to be monitored daily.
Healthcare pr Healthcare practitioners actitioners admit women with a diagnosis of pre-eclampsia to hospital and monitor their condition daily.
Commissioners Commissioners ensure they commission services that admit women with a diagnosis of preeclampsia to hospital and monitor their condition daily.
What the quality statement means for patients, service users and carers
W Women with pre-eclampsia omen with pre-eclampsia (a pregnancy-related rise in blood pressure with protein in the urine that happens in some pregnancies) are admitted to hospital and have their condition monitored every day (while in hospital and at home if they go home before their baby is born).
Source guidance
Hypertension in pregnancy (NICE clinical guideline 107) recommendation 1.5.1.2 (key priority for implementation).
Definitions of terms used in this quality statement
Integr Integrated package of care ated package of careNICE clinical guideline 107 recommends admission to hospital for women with pre-eclampsia as part of an integrated package of care. This covers admission to hospital, treatment, measurement of blood pressure, testing for proteinuria and blood tests.
Pre-eclampsia Pre-eclampsia New hypertension presenting after 20 weeks of pregnancy with significant Hypertension in pregnancy (QS35) Quality statement 6: Planning mode and timing of birth for women with Quality statement 6: Planning mode and timing of birth for women with pre-eclampsia pre-eclampsia
Quality statement
Women with pre-eclampsia have an agreed consultant obstetrician-led plan for the timing and mode of birth.
Rationale
Some women who have pre-eclampsia with mild or moderate hypertension will progress to severe pre-eclampsia, which is associated with serious adverse outcomes. Because the progress of the condition differs between women, a consultant-led plan should be developed for each woman with pre-eclampsia including acceptable thresholds for intervention of all monitored thresholds (maternal and fetal) for early birth. This will be agreed with the pregnant woman, updated as needed, and will supersede any original birth plan.
Quality measures
Structure Structure
Evidence of local arrangements to ensure that women with pre-eclampsia have an agreed consultant obstetrician-led plan for the timing and mode of birth.
Data sour
Process Process
Women with pre-eclampsia have an agreed consultant obstetrician-led plan for the timing and mode of birth documented in their notes.
Numerator -the number of women in the denominator who have an agreed consultant obstetrician-led plan for the timing and mode of birth documented in their notes.
Denominator -the number of women who have given birth who had pre-eclampsia. 
Data sour
What the quality statement means for service providers, healthcare practitioners and commissioners
Service pro Service providers viders ensure that there are local arrangements in place for women with pre-eclampsia to have an agreed consultant obstetrician-led plan for the timing and mode of birth.
Healthcare pr Healthcare practitioners actitioners ensure that women with pre-eclampsia have an agreed consultant obstetrician-led plan for the timing and mode of birth.
Commissioners Commissioners ensure they commission services that develop an agreed consultant obstetrician-W Women with pre-eclampsia omen with pre-eclampsia (a pregnancy-related rise in blood pressure with protein in the urine that happens in some pregnancies) and their consultant obstetrician agree a plan for when and how they will give birth and that the plan is followed.
Source guidance
Hypertension in pregnancy (NICE clinical guideline 107) recommendations 1.5.2.1, 1.5.2.2 (key priority for implementation), and 1.5.2.3-1.5.2.7.
Definitions of terms used in this quality statement
The consultant obstetrician-led plan consultant obstetrician-led plan should be agreed with both the pregnant woman and the multidisciplinary team providing the woman's care, including other specialists, in particular
anaesthetists. This should be done as soon after admission as possible. The birth should be according to the most up-to-date version of the plan.
Pre-eclampsia Pre-eclampsia New hypertension presenting after 20 weeks of pregnancy with significant proteinuria (urinary protein:creatinine ratio greater than 30 mg/mmol or a validated 24-hour urine collection result greater than 300 mg protein).
Timing and mode of birth Timing and mode of birth For indications for timing and mode of birth, see NICE clinical guideline 107 recommendations 1.5.2.1-1.5.2.7.
Quality statement 7: T Quality statement 7: Tr ransfer of information about ongoing management ansfer of information about ongoing management
Quality statement
Women who have had hypertension in pregnancy have a plan for ongoing antihypertensive management included in their postnatal care plan, which is communicated to their GP when they are transferred to community care after the birth.
Rationale
There are particular risks to women who have had hypertension in pregnancy (such as the risk of stroke) in the immediate postnatal period. The development of an individualised care plan for women who have had hypertension in pregnancy before they are transferred to community care
should support ongoing antihypertensive management and enable risks to be monitored and addressed, including variations in blood pressure.
Quality measures
Evidence of local arrangements to communicate a plan for ongoing antihypertensive management for women who had hypertension in pregnancy to their GP when they are transferred to community care after the birth.
Data sour
Process Process
The proportion of women with hypertension in pregnancy for whom a plan for ongoing antihypertensive management is communicated to their GP when they are transferred to community care after the birth.
Numerator -the number of women in the denominator for whom a plan for ongoing antihypertensive management is communicated to their GP when they are transferred to community care after the birth.
Denominator -the number of women who have given birth who had hypertension in pregnancy.
Data sour
Service pro Service providers viders ensure that local arrangements are in place to communicate a plan for ongoing antihypertensive management to GPs of women who had hypertension in pregnancy when they are transferred to community care after the birth.
Healthcare pr Healthcare practitioners actitioners communicate a plan for ongoing antihypertensive management to GPs of women who had hypertension in pregnancy when they are transferred to community care after the birth.
Commissioners Commissioners ensure they commission services that communicate a plan for ongoing antihypertensive management to GPs of women who had hypertension in pregnancy when they are transferred to community care after the birth.
What the quality statement means for patients, service users and carers
W Women who had h omen who had hypertension (high blood pressure ypertension (high blood pressure) in pregnancy ) in pregnancy have a plan for continuing management of their blood pressure, which is communicated to their GP when they go home after their baby is born.
Source guidance
Hypertension in pregnancy (NICE clinical guideline 107) recommendations 1.2.6.5, 1.4.3.5, 1.5.3.8 and 1.10.1.1.
Definitions of terms used in this quality statement
A plan for ongoing antih plan for ongoing antihypertensiv ypertensive management e management should include information about postpartum management, including a plan for ongoing management. NICE clinical guideline 107 recommends that a care plan should be written for women with gestational hypertension or pre-eclampsia who have given birth and are being transferred to community care that includes all of the following:
who will provide follow-up care, including medical review if needed frequency of blood pressure monitoring needed thresholds for reducing or stopping treatment 
Quality statement
Women who have had gestational hypertension or pre-eclampsia discuss future pregnancy and lifetime cardiovascular risks during a medical review at their 6-8 week postnatal medical check.
Rationale
The long-term risks for women who have had hypertension in pregnancy include developing high blood pressure and an increased lifetime cardiovascular risk. Increased awareness and surveillance may lead to earlier intervention, such as antihypertensive treatment, with likely benefits for the woman. Women should be made aware of risks in future pregnancies resulting from hypertension in a previous pregnancy.
Quality measures
Evidence of local arrangements for women who have had gestational hypertension or preeclampsia to have a discussion about future related risks during the medical review at their 6-8 week postnatal medical check.
Data sour
Process Process
The proportion of women who have had gestational hypertension or pre-eclampsia who have a discussion about future related risks during the medical review at their 6-8 week postnatal medical check.
Numerator -the number of women in the denominator who have a discussion about future related risks.
Denominator -the number of women who have had gestational hypertension or pre-eclampsia who have a medical review at their 6-8 week postnatal check.
Data sour
Service pro Service providers viders ensure that local arrangements are in place for women who have had gestational hypertension or pre-eclampsia to have a discussion about future related risks during the medical review at their 6-8 week postnatal medical check.
Healthcare pr Healthcare practitioners actitioners discuss future related risks with women who have had gestational hypertension or pre-eclampsia during the medical review at their 6-8 week postnatal medical check.
Commissioners Commissioners ensure that they commission services that discuss future related risks with women who have had gestational hypertension or pre-eclampsia during the medical review at their 6-8 week postnatal medical check.
What the quality statement means for patients, service users and carers
W Women who ha omen who hav ve had gestational h e had gestational hypertension (new high blood pressure starting after 20 weeks ypertension (new high blood pressure starting after 20 weeks of pregnancy) or pre-eclampsia of pregnancy) or pre-eclampsia (a pregnancy-related rise in blood pressure with protein in the urine that happens in some pregnancies) have an appointment with their doctor or midwife 6 to 8 weeks after they have had their baby, at which they discuss their risk of having problems with their blood pressure or pregnancies in the future.
Source guidance
Hypertension in pregnancy (NICE clinical guideline 107) recommendations 1.4.3.7, 1.5.3.10 (key priority for implementation), 1.10.1.1, 1.10.4.1 and 1.10.4.2 (key priority for implementation). gestational hypertension in a future pregnancy ranges from about 1 in 6 (16%) pregnancies to about 1 in 2 (47%) pregnancies pre-eclampsia in a future pregnancy ranges from 1 in 50 (2%) to about 1 in 14 (7%) pregnancies.
Definitions of terms used in this quality statement
Women who have had pre-eclampsia should be told that their risk of developing:
gestational hypertension in a future pregnancy ranges from about 1 in 8 (13%) pregnancies to about 1 in 2 (53%) pregnancies pre-eclampsia in a future pregnancy is up to about 1 in 6 (16%) pregnancies pre-eclampsia in a future pregnancy is about 1 in 4 (25%) pregnancies if their pre-eclampsia was complicated by severe pre-eclampsia, HELLP syndrome or eclampsia and led to birth before 34 weeks, and about 1 in 2 (55%) pregnancies if it led to birth before 28 weeks.
Gestational h Gestational hypertension ypertension New hypertension presenting after 20 weeks of pregnancy without significant proteinuria.
Medical re Medical review view
NICE clinical guideline 107 recommends that women who have had gestational hypertension or pre-eclampsia should be offered a medical review at their postnatal check, which takes place 6-8 weeks after birth. (Topic expert group consensus was that this would be carried out by a GP or an appropriately trained midwife.)
Equality and diversity considerations
Where information is provided, there must be equal access to information for all women, including those with additional needs, such as physical or learning disabilities, and those who do not speak or read English. Women receiving information should have access to an interpreter or advocate if needed.
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Using the quality standard Using the quality standard
Quality measures
The quality measures accompanying the quality statements aim to improve the structure, process and outcomes of care in areas identified as needing quality improvement. They are not a new set of targets or mandatory indicators for performance management.
We have indicated if current national indicators exist that could be used to measure the quality statements. These include indicators developed by the Health and Social Care Information Centre through its Indicators for Quality Improvement Programme. If there is no national indicator that could be used to measure a quality statement, the quality measure should form the basis for audit criteria developed and used locally.
See NICE's What makes up a NICE quality standard? for further information, including advice on using quality measures.
Levels of achievement
Expected levels of achievement for quality measures are not specified. Quality standards are intended to drive up the quality of care, and so achievement levels of 100% should be aspired to (or 0% if the quality statement states that something should not be done). However, NICE recognises that this may not always be appropriate in practice, taking account of safety, choice and professional judgement, and therefore desired levels of achievement should be defined locally.
Using other national guidance and policy documents
Other national guidance and current policy documents have been referenced during the development of this quality standard. It is important that the quality standard is considered by commissioners, providers, health and social care practitioners, patients, service users and carers alongside the documents listed in Development sources.
Information for commissioners
NICE has produced support for commissioning that considers the commissioning implications and potential resource impact of this quality standard. This is available on the NICE website.
Further explanation of the methodology used can be found in the quality standards Process guide on the NICE website.
Evidence sources
The documents below contain recommendations from NICE guidance or other NICE-accredited recommendations that were used by the Topic Expert Group to develop the quality standard statements and measures. 
